Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.61 |
| ▸ | CES2 | O00748 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | OGG1 | O15527 | 1/20 | 0.52 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6788006 | 0.83 | GSK3B (1.00) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL241664 | 0.82 | GSK3B (0.70) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL1305020 | 0.82 | GSK3B (0.70) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL70930 | 0.80 | GSK3B (1.00) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL55916 | 0.80 | GSK3B (0.67) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL301099 | 0.78 | GSK3B (0.64) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL474016 | 0.78 | GSK3B (0.64) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL3182097 | 0.78 | GSK3B (0.64) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL301100 | 0.78 | GSK3B (0.64) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL8751033 | 0.78 | GSK3B (0.64) | GSK3BHDAC1HDAC8HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4067866-A | Process for preparing cephalosporins and certain novel 2β-thiohydrazo-azetidinones as intermediates | SOCIETA' FARMACEUTICI ITALIA (IT) | 1978-01-10 | — | — | US | claimed |
| WO-2023234187-A1 | METHOD FOR PRODUCING ORGANIC COPPER COMPOUND | シンクレスト株式会社 | 2023-12-07 | — | — | WO | disclosed |
| WO-2023120647-A1 | ORGANIC COPPER COMPOUND, AND METHOD FOR PRODUCING ORGANIC COPPER COMPOUND | シンクレスト株式会社 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023120645-A1 | ORGANIC ZINC COMPOUND AND PRODUCTION METHOD FOR ORGANIC ZINC COMPOUND | シンクレスト株式会社 | 2023-06-29 | — | — | WO | disclosed |
| US-9981008-B2 | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2018-05-29 | — | — | US | disclosed |
| EP-2939683-B1 | Apolipoprotein A-I Mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2017-01-04 | — | — | EP | disclosed |
| US-20160324923-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2016-11-10 | — | — | US | disclosed |
| US-9388232-B2 | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2016-07-12 | — | — | US | disclosed |
| EP-2939683-A1 | Apolipoprotein A-I Mimics | Cerenis Therapeutics Holding SA (FR) | 2015-11-04 | — | — | EP | disclosed |
| EP-2396017-B1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2015-07-01 | — | — | EP | disclosed |
| US-8993597-B2 | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2015-03-31 | — | — | US | disclosed |
| US-20130231459-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2013-09-05 | — | — | US | disclosed |
| US-8378068-B2 | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2013-02-19 | — | — | US | disclosed |
| US-20100267631-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2010-10-21 | — | — | US | disclosed |
| US-4234578-A | ANTIBIOTICS | CIBA-GEIGY CORPORATION (US) | 1980-11-18 | — | — | US | disclosed |
| US-4133814-A | ANTITUMOR AGENTS | ELI LILLY AND COMPANY (US) | 1979-01-09 | — | — | US | disclosed |
| US-4075227-A | NONSTEROIDAL | ELI LILLY AND COMPANY (US) | 1978-02-21 | — | — | US | disclosed |
| US-4075223-A | NONSTEROIDAL | ELI LILLY AND COMPANY (US) | 1978-02-21 | — | — | US | disclosed |
| US-4024249-A | FOR COMBATTING MICROORGANISMS | CIBA-GEIGY CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
| US-4017546-A | AROYL PHENYL INDENES AND AROYL PHENYL NAPHTHALENES | ELI LILLY AND COMPANY (US) | 1977-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267631-A1 | APOLIPOPROTEIN A-I MIMICS | APOB, APOL1, LIPG | GSK3B 3441/4885HDAC1 3318/4885HDAC8 3979/4885 |
| US-20160324923-A1 | APOLIPOPROTEIN A-I MIMICS | APOB, APOL1, LIPG | GSK3B 3441/4885HDAC1 3318/4885HDAC8 3979/4885 |
| US-20130231459-A1 | APOLIPOPROTEIN A-I MIMICS | APOB, APOL1, LIPG | GSK3B 3441/4885HDAC1 3318/4885HDAC8 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.